Ubiquitination at the interface of tumor viruses and DNA damage responses.

Curr Opin Virol

Division of Protective Immunity and Division of Cancer Pathobiology, Children's Hospital of Philadelphia, Philadelphia, PA, USA; Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA. Electronic address:

Published: October 2018


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Viruses exploit cellular ubiquitination machinery to shape the host proteome and promote productive infection. Among the cellular processes influenced by viral manipulation of ubiquitination is the DNA damage response (DDR), a network of cellular signaling pathways that sense and respond to genomic damage. This host-pathogen interaction is particularly important during virus replication and transformation by DNA tumor viruses. Manipulating DDR pathways can promote virus replication but also impacts host genomic instability, potentially leading to cellular transformation and tumor formation. We review ways in which viruses are known to hijack the cellular ubiquitin system to reshape host DDR pathways.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6263849PMC
http://dx.doi.org/10.1016/j.coviro.2018.08.017DOI Listing

Publication Analysis

Top Keywords

tumor viruses
8
dna damage
8
virus replication
8
ddr pathways
8
cellular
5
ubiquitination interface
4
interface tumor
4
viruses
4
viruses dna
4
damage responses
4

Similar Publications

For some of the COVID-19 vaccines, the drug substances released to market were manufactured differently than those used in clinical trials. Manufacturing nucleoside-modified mRNA (modRNA) for commercial COVID-19 vaccines relies on RNA polymerase transcription of a plasmid DNA template. Previous studies identified high levels of plasmid DNA in vials of modRNA vaccines, suggesting that the removal of residual DNA template is problematic.

View Article and Find Full Text PDF

Background: Human papillomavirus (HPV) vaccination is a well-established global strategy for the prevention of cervical cancer. However, the uptake of the vaccine varies across regions and countries due to several factors. Although girls are at risk for cervical cancer, there are limited studies measuring vaccination uptake among female adolescents in the study area.

View Article and Find Full Text PDF

Conserved and distinct expression of circular RNAs in commercially used Marek's disease vaccine viruses.

J Gen Virol

September 2025

Namur Research Institute for Life Sciences (NARILIS), Integrated Veterinary Research Unit (URVI), University of Namur, Namur, Belgium.

Circular RNAs (circRNAs) are covalently closed RNA molecules, supporting a wide diversity of functions. While aberrant circRNA expression stands as a recognized hallmark of cancer development, our attention has turned to investigating their role in viral infections, specifically (GaHV-2, Marek's disease virus) infection. In a previous study focused on the virulent GaHV-2 strain, RB-1B, we extensively catalogued circRNAs produced from virulence genes, notably from the MEQ-vIL-8 and the latency-associated transcripts (LATs) gene.

View Article and Find Full Text PDF

HPV vaccination in adults provides opportunities for individuals who were previously ineligible, or who missed vaccination as adolescents, thereby reducing HPV-related disease burden. This targeted literature review summarizes the HPV vaccination recommendations and guidelines by National Immunization Technical Advisory Groups and professional societies, and public funded programs for adults. Of the 152 jurisdictions examined, 62 offered HPV vaccination recommendations for general adults.

View Article and Find Full Text PDF

Clinical Pharmacology Characterization of the First-In-Class Oncolytic Viral Therapy T-VEC in Adults and Pediatric Subjects.

J Clin Pharmacol

September 2025

Clinical Pharmacology, Modeling and Simulation, Amgen Inc., South San Francisco, CA, USA.

Oncolytic viruses are an emerging class of immunotherapies for cancer treatment. Talimogene laherparepvec (T-VEC) is a first-in-class oncolytic virus approved globally for advanced melanoma. Herein, we describe the quantitative clinical pharmacology aspects of T-VEC that supported the development of this unique therapy.

View Article and Find Full Text PDF